In December, Anavex stated:
<The Company filed an IND for ANAVEX®2-73 in Rett syndrome, for which the Company received orphan drug designation by the FDA, and is expecting feedback from the FDA to finalize the clinical trial protocol for this study.>
The sentence makes it clear that Anavex expected to make changes before resubmitting the IND to the FDA. In February, it was stated:
<In consideration of the new genomic results, the investigational new drug application (IND) filing for ANAVEX®2-73 for the treatment of Rett syndrome will be updated and submitted during the current quarter to include this data.>
I do not see a contradiction in yesterday's press release that, in fact, the updated IND was submitted during the first quarter.